Department of General Surgery, The First Affiliated Hospital of Xiamen University, Xiamen, Xiamen Fujian, China.
Department of Gastrointestinal Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.
Biosci Rep. 2022 Jun 30;42(6). doi: 10.1042/BSR20220225.
X-box binding protein 1 (XBP1) is mainly expressed in breast cancer (BC) in human cancers. Its tumorigenesis and favourable prognosis are contradictory, and its essential role in chemotherapeutic response and immunosuppression is unknown in BC. The study firstly identified XBP1 who received neoadjuvant chemotherapy (NAC) from GSE25055 and GSE24460. Associations between XBP1 expression and clinicopathological characteristics was investigated using Oncomine, TCGA, UALCAN and bc-GenExMiner. The prognostic value of XBP1 was assessed using the Kaplan-Meier Plotter, bc-GenExMiner, GSE25055, and GSE25056. Furthermore, we systematically correlated XBP1 and immunological characteristics in the BC tumour microenvironment (TME) using TISIDB, TIMER, GSE25055, GSE25056 and TCGA dataset. Finally, an essential role of XBP1 in chemotherapy response was evaluated based on GSE25055, GSE25065, GSE24460, GSE5846, ROC Plotter and CELL databases. Furthermore, XBP1 mRNA expression levels were obviously highest in BC among human cancers and were significantly related to a good prognosis. In addition, XBP1 mRNA and protein levels were higher in the luminal subtype than in normal tissues and basal-like subtype, which might be attributed to membrane transport-related processes. Apart from BC, negative immunological correlations of XBP1 were not observed in other malignancies. XBP1 might shape the non-inflamed TME in BC. Finally, XBP1 expression was higher in chemo-resistive than chemo-sensitive cases, it had a predictive value and could independently predict chemotherapy response in BC patients receiving NAC. Our study suggests that the essential role of XBP1 in clinical pathologic features, non-inflamed TME, chemotherapy response in BC.
X 盒结合蛋白 1（XBP1）主要在人类癌症中的乳腺癌（BC）中表达。其致癌性和有利的预后是矛盾的，其在 BC 中的化疗反应和免疫抑制中的重要作用尚不清楚。本研究首先从 GSE25055 和 GSE24460 中鉴定出接受新辅助化疗（NAC）的 XBP1。使用 Oncomine、TCGA、UALCAN 和 bc-GenExMiner 研究 XBP1 表达与临床病理特征之间的关联。使用 Kaplan-Meier Plotter、bc-GenExMiner、GSE25055 和 GSE25056 评估 XBP1 的预后价值。此外，我们使用 TISIDB、TIMER、GSE25055、GSE25056 和 TCGA 数据集系统地将 XBP1 与 BC 肿瘤微环境（TME）中的免疫特征相关联。最后，根据 GSE25055、GSE25065、GSE24460、GSE5846、ROC Plotter 和 CELL 数据库评估 XBP1 在化疗反应中的重要作用。此外，XBP1mRNA 表达水平在 BC 中在人类癌症中明显最高，与良好的预后显著相关。此外，XBP1mRNA 和蛋白水平在腔型亚型中高于正常组织和基底样亚型，这可能归因于膜转运相关过程。除了 BC 之外，在其他恶性肿瘤中未观察到 XBP1 的负免疫相关性。XBP1 可能塑造 BC 中的非炎症性 TME。最后，XBP1 在化疗耐药性病例中的表达高于化疗敏感性病例，它具有预测价值，可以独立预测接受 NAC 的 BC 患者的化疗反应。我们的研究表明，XBP1 在 BC 的临床病理特征、非炎症性 TME、化疗反应中具有重要作用。
